Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) FCF Margin (2019 - 2025)

Keros Therapeutics' FCF Margin history spans 6 years, with the latest figure at 4485.27% for Q4 2025.

  • For Q4 2025, FCF Margin fell 1359885.0% year-over-year to 4485.27%; the TTM value through Dec 2025 reached 44.01%, down 13562265.0%, while the annual FY2025 figure was 44.05%, N/A changed from the prior year.
  • FCF Margin reached 4485.27% in Q4 2025 per KROS's latest filing, down from 12.94% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1050500.0% in Q1 2021 to a low of 408362.5% in Q3 2023.
  • Average FCF Margin over 5 years is 50148.03%, with a median of 135.1% recorded in 2025.
  • Peak YoY movement for FCF Margin: plummeted -105050841bps in 2022, then skyrocketed 40010013bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 110.19% in 2021, then surged by 92bps to 8.41% in 2022, then crashed by -216048bps to 18180.42% in 2023, then soared by 150bps to 9113.58% in 2024, then crashed by -149bps to 4485.27% in 2025.
  • Per Business Quant, the three most recent readings for KROS's FCF Margin are 4485.27% (Q4 2025), 12.94% (Q3 2025), and 160.02% (Q2 2025).